Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 0 | 1M |
| Operating Income | -110M | -102M | -103M | -62M | -50M |
| EBITDA | -110M | -101M | -102M | -61M | -49M |
| Net Income | -96M | -89M | -90M | -60M | -50M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.03
-8.44% today
1Y Change
-11.11%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Terns Pharmaceuticals, Inc. (TERN) is a Healthcare stock with a market cap of $4.77B and listed on NASDAQ. The stock last traded around $1.03 and down 11.1% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +8.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +8.0%, free cash flow -17.3% with operating margin 0.0% and ROIC -10.9%. Stock Foundry combines TERN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TERN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TERN Max Drawdown
-75.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TERN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.0M
FY Net Income
-$50.2M
+16.9% YoY
Free Cash Flow
-$42.2M
+14.6% YoY
Revenue Growth
+0.0%
EPS Growth
+8.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 0 | 1M |
| Operating Income | -110M | -102M | -103M | -62M | -50M |
| EBITDA | -110M | -101M | -102M | -61M | -49M |
| Net Income | -96M | -89M | -90M | -60M | -50M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 525M | 161M | 80M | 143M | 48M |
| Total Assets | 1.0B | 364M | 269M | 287M | 168M |
| Total Liabilities | 19M | 18M | 13M | 10M | 8M |
| Shareholder Equity | 1.0B | 346M | 255M | 277M | 160M |
| Total Debt | 919K | 1M | 603K | 1M | 0 |
| Net Debt | -524M | -160M | -79M | -142M | -48M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
42M
+14.8% YoY
Capital Expenditures
340K
-23.6% YoY
Free Cash Flow
42M
+14.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-20.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.